Elena Pasini

@isnb.it

UOC of Neurology
IRCCS Istituto delle Scienze Neurologiche di Bologna

Elena Pasini


               Download Compact PDF  
https://researchid.co/elena.pasini
- 01/06/2020-Today: Neurologist at Bellaria Hospital, UOC of Neurology, IRCCS of Neurological Sciences of Bologna
- 06/11/2017-31/05/2020: Neurologist at Maggiore Hospital, UOC of Neurology, IRCCS of Neurological Sciences of Bologna
- 14/03/2016-05/11/2017: Research project on “Clinical evaluation and therapeutic treatment of serious neurological diseases that need management in ICU through multiparametric and neurophysiological monitoring” at Bellaria Hospital, IRCCS of Neurological Sciences of Bologna
- 08/24/2009-05/14/2010: fellowship in PERNO project (Progetto Emiliano-Romagnolo in Neuro-Oncologia-Sottoprogetto Epilessia tumorale) at the Neurological Department of Bellaria Hospital (referent Dr. Michelucci)
- In 2008-2009 partecipation to two randomized clinical trials on new epileptic drugs at the Neurological Department of Bellaria Hospital (referent Dr. Michelucci)

EDUCATION

- Scientific-technological diploma in 2002 (vote 100/100)
- Nine months spent at the Pasteur University of Strasbourg, France, during university
- Undergraduate Introduction to Management Program, BU Global, Boston University (07-08/2007)
- Graduated in Medicine and Surgery at the “Alma Mater Studiorum University of Bologna” on May 12, 2008 with 110/110 and Praise. Title of thesis: “amyotrophic lateral sclerosis: genotype-phenotype correlation in patients with SOD1 gene mutation and etiopathogenic hypothesis. Supervisor: Prof. Carlo Alberto Tassinari.
- From the 24th March 2009 entered in the order of Bologna physicians
- 05/17/2010-01/02/2016 Neurological Fellowship at Bologna University (headmaster Prof. Paolo Tinuper).
- 25/2/2012-06/04/2012 “EFNS Department to Department Program” at the “National Hospital of Neurology and Neurosurgery-Department of Neurology, Queen Square, London” (Prof. Simon Shorvon)

RESEARCH INTERESTS

Epilepsy
EEG
Stereo-EEG
ICU-monitoring

FUTURE PROJECTS

Stereo-EEG

During 2022-2025 we expect to begin the stereo-electroencephalography study of the patient affected by cryptogenic focal pharmacoresistant epilepsy. All this project will be possible thanks to the collaboration with the collegues of Niguarda Hospital of Milan. Project financed by the Emilia-Romagna Region


Applications Invited

Neuro-critical care unit monitoring

During the last years we improve our experience in the field of the long term monitorig EEG and therapy of refractory and super refractory status epilepticus. At the same time we pursuit an important project of multidisciplinary evaluation of the long term prognosis in patients with severe brain injuries


Applications Invited

Lafora Disease

Clinical and electrophysiological characterization of Lafora affected patients


Applications Invited
80

Scopus Publications

1923

Scholar Citations

25

Scholar h-index

39

Scholar i10-index

Scopus Publications

  • Integration of intraoperative ultrasound and depth-electrode electrocorticography for resection guidance in epilepsy surgery: technical workflow and feasibility
    Luca Zanuttini, Elena Pasini, Lorenzo Ferri, Lidia Di Vito, Anna Scarabello, et al.
    Acta Neurochirurgica, 2026
    Background Complete resection of the epileptogenic zone (EZ) is the strongest predictor of seizure freedom in drug-resistant epilepsy (DRE). However, even in MRI-positive cases with anatomo-electro-clinical concordance, the EZ may not be clearly delineated, complicating intraoperative decision-making. Intraoperative ultrasound (ioUS) provides real-time anatomical feedback, while depth-electrode intraoperative electrocorticography (iECoG) enables electrophysiological delineation of epileptogenic tissue beyond the cortical surface, sampling deep regions not accessible to subdural electrodes. Their integration may improve intraoperative precision in defining resection limits and optimizing resective surgery. Methods This study describes the workflow and feasibility of combining ioUS and depth-electrode iECoG for intraoperative guidance in MRI-positive focal DRE with an ill-defined EZ. In all cases, concordant anatomo-electro-clinical data identified a single EZ for which SEEG was not required, yet the suspected EZ remained poorly delineated. ioUS was used for real-time lesion visualization, verification of electrode trajectories, and guidance of resection depth and extent. Pre- and post-resective depth-electrode iECoG and ioUS were used in combination to delineate the resection margins, by identifying interictal epileptiform discharges (IEDs) and confirming lesion boundaries and resection completeness. Results Six patients underwent resective surgery using the combined ioUS–iECoG workflow. The technique was feasible and safe in all cases, with no intraoperative or postoperative complications (37 depth-electrode insertions). iECoG revealed IEDs in four patients (66%), prompting resection extension in two. MRI confirmed complete resection in all cases. At last follow-up (6–40 months), 5/6 patients were seizure-free (Engel I). Histopathology revealed FCD IIb in three cases, a gliotic lesion related to an encephalocele in one, a gliotic scar post–arachnoid cyst marsupialization in another, and a tuberous sclerosis–related lesion in a case of tuberous-sclerosis-complex. Conclusion The integration of ioUS and depth-electrode iECoG offers real-time anatomical and electrophysiological data, refining EZ delineation and resection assessment in complex MRI-positive epilepsy cases where SEEG is not clinically indicated.
  • Accuracy of MRI compared with DSA for vascular mapping in SEEG trajectory planning
    Francesca Vari, Luca Zanuttini, Elena Pasini, Lorenzo Ferri, Lidia di Vito, et al.
    Journal of Clinical Neuroscience, 2026
  • Exploring pathways leading to drug-resistant epilepsy for patients with cryptogenic new onset refractory status epilepticus
    Aurélie Hanin, Clémence Marois, Martin Guillemaud, Mario Chavez, Léa Cosme, et al.
    Epilepsia, 2026
    Objective Cryptogenic new onset refractory status epilepticus (cNORSE) carries high risks of long‐term disability and post‐NORSE epilepsy, but mechanisms remain unclear. We aimed to assess the predictive value of inflammatory and brain injury biomarkers and determine whether immune disturbances persist in the chronic phase. Methods We enrolled 93 cNORSE patients from the Pitié‐Salpêtrière Hospital and the Yale NORSE/FIRES biorepository (2013–2025). Serum and cerebrospinal fluid (CSF) samples were collected during status epilepticus (SE), with outcomes assessed 6–12 months after resolution. To investigate post‐cNORSE epilepsy, we compared 39 post‐cNORSE patients (25 with paired acute samples) to 40 patients with temporal lobe epilepsy due to hippocampal sclerosis (TLE‐HS) and 20 with chronic immune‐mediated encephalitis. Results During cNORSE, elevated innate cytokines (serum CXCL8, CCL2; CSF IL‐6, CXCL8, CCL2, MIP‐1α, G‐CSF) and brain injury biomarkers (serum and CSF neurofilament light chain [NfL], CSF neuron‐specific enolase) correlated with worse functional outcomes. Multivariate models demonstrated that adding serum NfL to cytokines improved poor outcome prediction (area under the curve = .75). In contrast, no acute biomarker predicted post‐cNORSE epilepsy, which was instead associated with prolonged SE, magnetic resonance imaging abnormalities, and the need for more intensive treatment. In paired analyses, most serum cytokines normalized during the chronic phase, particularly IL‐6, IL‐10, and IL‐1β, although new adaptive immune disturbances (IL‐17A, IL‐12p70, TNFα) appeared in 20% of patients. No chronic elevations of innate cytokines were observed in post‐cNORSE patients. Conversely, elevated age‐adjusted NfL levels were more frequent in post‐cNORSE epilepsy (64%) than encephalitis (45%) and TLE‐HS (20%), ( p < .001), with elevated NfL levels correlating with poor functional outcomes ( p = .019). Significance Innate immune activation is a hallmark of acute cNORSE but largely resolves in the chronic phase, arguing against persistent innate inflammation as the driver of post‐cNORSE epilepsy. In contrast, persistently elevated NfL levels suggest ongoing axonal injury, potentially contributing to poor outcomes. Integrating inflammatory and neuroaxonal injury biomarkers may improve risk stratification and guide long‐term management.
  • Extreme cryptogenic new onset refractory status epilepticus/febrile infection-related epilepsy syndrome: Evidence of profound neuroinflammation and neuronal injury
    Lorenzo Muccioli, Lorenzo Ferri, Lidia Di Vito, Elena Pasini, Barbara Mostacci, et al.
    Epilepsia, 2026
  • Predicting epilepsy after new onset refractory status epilepticus due to autoimmune encephalitis: The DAME score
    Simona Lattanzi, Sara Matricardi, Alberto Vogrig, Giada Pauletto, Margherita Nosadini, et al.
    Epilepsia, 2026
    Objective This study aimed to identify risk factors and develop a predictive scoring system for autoimmune‐associated epilepsy in subjects with autoimmune encephalitis presenting with new onset refractory status epilepticus (NORSE). Methods This retrospective, multicenter, cohort study included subjects who presented with NORSE at the onset of autoimmune encephalitis and had at least 24 months of follow‐up after immunotherapy. The outcome was the development of autoimmune‐associated epilepsy, defined as persistent seizures despite adequate immunotherapy and absence of active inflammation. Factors independently associated with the outcome were identified through a backward stepwise selection. Adjusted regression coefficients of each independent predictor were transformed to produce a points‐based risk‐scoring system. Results Seventy participants were included (median age = 24.2 years, 38.6% male). During a median follow‐up of 53 months, 54.3% of subjects developed autoimmune‐associated epilepsy. Status epilepticus duration ≥ 10 days (odds ratio [OR] = 31.14, 95% confidence interval [CI] = 2.12–456.87, p = .012), positivity for antibodies against surface antigens (OR = .12, 95% CI = .02–.85, p = .034), bitemporal magnetic resonance imaging (MRI) abnormalities suggestive of autoimmune encephalitis during acute stage (OR = 49.80, 95% CI = 2.95–841.77, p = .007), and interictal epileptiform discharges during electroencephalographic (EEG) follow‐up (OR = 71.32, 95% CI = 6.48–785.32, p < .001) were independently associated with the study outcome. The duration–antibodies–MRI–EEG (DAME) score was developed as an integer‐based scoring system predictive of autoimmune‐associated epilepsy. With an optimal cutoff of ≥3 points, it yielded a sensitivity of 86.8%, a specificity of 87.5%, and an overall accuracy of 87.1%. Significance The DAME score could serve as a user‐friendly score to predict the risk of autoimmune‐associated epilepsy in patients with NORSE due to autoimmune encephalitis.
  • Seizure Clusters: Current Concepts in Definition and Treatment
    Gemma Bassani, Elena Pasini, Barbara Mostacci, Lidia Di Vito, Lorenzo Ferri, et al.
    Journal of Clinical Medicine, 2026
    Seizure clusters (SCs) are an acute and transient increase in seizure frequency relative to an individual patient’s baseline and are associated with an increased risk of injury, morbidity, and potentially mortality if not promptly and adequately treated. Despite their clinical importance, the management of SCs remains highly heterogeneous, primarily due to the absence of a universally accepted definition, which is determined also by the wide variability in seizure semiology and baseline individual burden;, as well as by differences in care settings. Outpatient treatment relies largely on caregivers’ ability to recognize SCs and administer rescue medication, whereas inpatient management may also involve invasive routes of administration. We conducted a literature review identifying 32 original articles addressing the treatment of SCs. The analysis focused on definitions, efficacy outcomes, and adverse events across three clinical scenarios: outpatient, Emergency Department (EDs) and Epilepsy Monitoring Units. The results show that in the outpatient setting, the available evidence suggests that diazepam nasal spray (DZP-NS), midazolam nasal spray (MDZ-NS), and oral lorazepam (LZP) solution may demonstrate comparable efficacy and safety. However, comparisons are limited by heterogeneity in studies’ designs, patient populations and outcome definitions, as well as by the absence of head-to-head trials. Moreover, geographic differences in drug availability (e.g., USA vs. Europe) limit the development of universally applicable treatment protocols. Consequently, the off-label use of oral benzodiazepines, including clobazam, clonazepam, and lorazepam, remains common when oral therapy is feasible, despite limited evidence. The implementation of a patient-specific Acute Seizure Action Plan (ASAP) incorporating an individualized SC definition is recommended. In contrast, inpatient management shows greater consensus, largely reflecting first-line treatment paradigms for status epilepticus. These include prompt intravenous benzodiazepine administration, followed by the intravenous loading of antiseizure medications such as brivaracetam or lacosamide in cases of seizure recurrence. In ED settings, “empirical” definitions of SCs (i.e., more than three seizures within 24 h) may facilitate timely intervention.
  • CSF1R mutations in an Italian population of early-onset dementia: a case series
    Beatrice Pancaldi, Andrea Mastrangelo, Alessandro Zilioli, Edoardo Ruggeri, Veria Vacchiano, et al.
    Journal of Neurology, 2026
    The diagnostic approach to subjects with early-onset dementia (EOD) is often challenging due to the broader range of possible etiologies as compared to late-onset dementia cases. Pathogenic variants in CSF1R gene have been increasingly reported in subjects with EOD, mostly clinically mimicking behavioral variant of frontotemporal dementia (bvFTD). Here we screened for variants in CSF1R gene in a large cohort of dementia patients consecutively referred for genetic analysis to an Italian tertiary center between 2005 and 2024 ( n = 2163). Sequence of CSF1R gene was determined with next-generation sequencing through either a dedicated panel or whole-exome sequencing. Pathogenic variants or variants of uncertain significance with higher evidence of pathogenicity were found in four participants (one female); three of these were not previously reported. Clinical data were collected, including brain magnetic resonance imaging and neuropsychological assessment. Cerebrospinal fluid (CSF) levels of neurofilament light chain (NfL) protein were measured. A family history of dementia was present in one subject. Mean age at onset was 51.5. Seizures were the presenting symptom in two cases and later appeared in other two. Two subjects presented with behavioral disturbances, resembling early bvFTD. Neuropsychological assessment revealed executive and language impairment in most cases. Anterior-predominant atrophy, symmetric white-matter involvement, and serpentine calcifications were the most common imaging abnormalities. High CSF NfL levels were found in all cases, with two of them showing markedly elevated values. CSF1R-related disease should be considered in EOD subjects, especially those presenting with executive/language deficits, seizures, white matter involvement, and markedly elevated CSF NfL levels.
  • Anti-seizure prophylaxis in brain tumors: An Italian survey among epileptologists
    Elena Pasini, Giada Pauletto, Marta Maschio, Roberto Michelucci, and
    Epilepsia Open, 2026
  • New therapeutic strategies for Lafora disease: Evaluation of the safety, efficacy, pharmacokinetics and metabolomic profile of intravenous VAL-1221 treatment
    Lorenzo Muccioli, Maria Tappatà, Andrea Farolfi, Pankaj K. Singh, Elena Pasini, et al.
    Neurotherapeutics, 2026
  • Clinical course and management challenges in Lafora disease: a narrative analysis in an Apulian cohort
    Giuseppe d’Orsi, Maria Teresa Di Claudio, Antonella Liantonio, Paola Imbrici, Cosimo Damiano Altomare, et al.
    Orphanet Journal of Rare Diseases, 2025
    Background Lafora disease (LD) is an ultra-rare, autosomal recessive neurodegenerative disorder characterized by the accumulation of Lafora bodies in the brain, leading to drug-resistant epilepsy, myoclonus, progressive dementia, and cerebellar dysfunction. This retrospective study describes the clinical course and management challenges of LD in a cohort of patients from the Apulia region of Southern Italy, where the disease prevalence appears to be higher than in other populations. Methods We retrospectively analyzed clinical, electroencephalographic, and management data from six unrelated families with a confirmed diagnosis of LD, followed at the Neurology Unit of the Scientific Institute Casa Sollievo della Sofferenza Hospital between 2010 and 2024. Demographic information, clinical presentation, treatment history, disease progression, and outcomes were collected. Results Our analysis identified three distinct electroclinical stages: an initial Presenting Symptoms Stage with the onset of seizures and subsequent development of myoclonus; a Progressive Neurodegeneration Stage characterized by drug-resistant epilepsy, dementia, and ataxia; and a Terminal Stage marked by severe disability, frequent seizure emergencies, and medical complications. Management in the late stages proved particularly challenging, requiring a multidisciplinary approach to address refractory seizures, status epilepticus, and medical complications such as aspiration pneumonia and respiratory failure. Home-based care, with specialized team support, played a crucial role in minimizing hospitalizations. Discussion Our findings underscore the importance of early diagnosis and a multidisciplinary approach in the management of LD. The late stages of the disease are characterized by significant clinical challenges necessitating close collaboration among neurologists, epileptologists, and other healthcare professionals, supported by effective home-based care. The apparent higher prevalence in Apulia warrants further investigation into potential genetic or environmental factors. Conclusion This study highlights the significant clinical burden of LD and emphasizes the importance of multidisciplinary management, particularly in the advanced stages. Home-based care supported by specialized teams and caregivers is essential for optimizing patient well-being. Further research is needed to identify early biomarkers and develop targeted therapies for this devastating condition.
  • The challenge of ultra-rarity: Dual diagnosis of Lafora disease and developmental encephalopathies linked to TRIO and SHANK3 pathogenic variants
    Lorenzo Muccioli, Francesca Bisulli, Raffaella Minardi, Maria Lucia Valentino, Micaela De Simone, et al.
    Epilepsia Open, 2025
  • Standard complete blood count to predict long-term outcomes in febrile infection–related epilepsy syndrome (FIRES): A multicenter study
    Martin Guillemaud, Aurélie Hanin, James J. Riviello, Mario Chavez, Ayush Batra, et al.
    Epilepsia, 2025
  • Trends in epilepsy surgery in Italy before and after the COVID-19 pandemic: A nationwide study
    Giuseppe Didato, Federico Vigevano, Laura Tassi, Renzo Guerrini, Marco de Curtis, et al.
    Epilepsia, 2025
  • Sleep and Awake EEG Findings in a Patient with Lafora Disease: From Presymptomatic to Overt Disease Stage
    Elena Pasini, Greta Mainieri, Irene Minardi, Serena Mazzone, Maria Tappatà, et al.
    Neurology Clinical Practice, 2025
  • Tumor-related epilepsy in glioma: A multidisciplinary overview
    Roberto Michelucci, Giada Pauletto, Antonio Silvani, Elena Pasini, Tamara Ius, et al.
    Epilepsia, 2025
  • Generation of a human induced pluripotent stem cell line (CIBIOi007-A) from a Lafora disease patient
    Gabriele Trentini, Giulia Cazzanelli, Marina Cardano, Orazio Palumbo, Mario Benvenuto, et al.
    Stem Cell Research, 2025
  • New onset refractory status epilepticus: Long-term outcomes beyond seizures
    Poul H. Espino, Krista Eschbach, Leah J. Blank, Mackenzie C. Cervenka, Eyal Muscal, et al.
    Epilepsia, 2025
  • Prognostic factors and impact of management strategies for status epilepticus: The STEPPER study in the Emilia-Romagna region, Italy
    Lidia Di Vito, Eleonora Matteo, Stefano Meletti, Corrado Zenesini, Giorgia Bernabè, et al.
    Epilepsia, 2025
  • Causes of hospitalization and mortality in persons with epilepsy: The EpiLink Bologna cohort, Italy
    Lorenzo Muccioli, Corrado Zenesini, Laura Licchetta, Laura Maria Beatrice Belotti, Lidia Di Vito, et al.
    European Journal of Neurology, 2025
  • Secondary sclerosing cholangitis in critically ill patients with febrile infection-related epilepsy syndrome (FIRES): a case series
    Lorenzo Muccioli, Lidia Di Vito, Elena Pasini, Lorenzo Ferri, Giovanni Vitale, et al.
    Frontiers in Neurology, 2025
  • CASPR2-related epilepsy: A distinctive and unrecognized form of epilepsy in adult and elderly males
    Roberto Michelucci, Elena Pasini, Patrizia Riguzzi, Maria Tappatà, Maria Pia Giannoccaro, et al.
    Epileptic Disorders, 2024
  • Parameter analysis in stereoelectroencephalography-guided radiofrequency thermocoagulation: A common basis for objective comparison between protocols
    Luca Zanuttini, Federico Mason, Lorenzo Ferri, Elena Pasini, Lidia Di Vito, et al.
    Epilepsy Research, 2024
  • VAL-1221 for the treatment of patients with Lafora disease: Study protocol for a single-arm, open-label clinical trial
    Lorenzo Muccioli, Luca Vignatelli, Maria Tappatà, Serena Mazzone, Corrado Zenesini, et al.
    BMJ Open, 2024
  • Cortical Connectivity Response to Hyperventilation in Focal Epilepsy: A Stereo-EEG Study
    Lorenzo Ferri, Federico Mason, Lidia Di Vito, Elena Pasini, Roberto Michelucci, et al.
    Applied Sciences Switzerland, 2024
  • Clinical practice guidelines on the management of status epilepticus in adults: A systematic review
    Luca Vignatelli, Valentina Tontini, Stefano Meletti, Maria Camerlingo, Stefania Mazzoni, et al.
    Epilepsia, 2024

RECENT SCHOLAR PUBLICATIONS

  • Accuracy of MRI compared with DSA for vascular mapping in SEEG trajectory planning
    F Vari, L Zanuttini, E Pasini, L Ferri, L di Vito, F Bisulli, M Dall’Olio, ...
    Journal of Clinical Neuroscience 149, 112026 , 2026
    2026
  • Exploring pathways leading to drug‐resistant epilepsy for patients with cryptogenic new onset refractory status epilepticu s
    A Hanin, C Marois, M Guillemaud, M Chavez, L Cosme, Z Hayatou, ...
    Epilepsia 67 (5), 2326-2346 , 2026
    2026
    Citations: 1
  • Extreme cryptogenic new onset refractory status epilepticus/febrile infection‐related epilepsy syndrome: Evidence of profound neuroinflammation and neuronal injury
    L Muccioli, L Ferri, L Di Vito, E Pasini, B Mostacci, CA Castioni, F Bisulli
    Epilepsia 67 (4), 2041-2044 , 2026
    2026
  • Predicting epilepsy after new onset refractory status epilepticus due to autoimmune encephalitis: The DAME score
    S Lattanzi, S Matricardi, A Vogrig, G Pauletto, M Nosadini, S Sartori, ...
    Epilepsia 67 (4), 1792-1801 , 2026
    2026
    Citations: 1
  • Seizure Clusters: Current Concepts in Definition and Treatment
    G Bassani, E Pasini, B Mostacci, LD Vito, L Ferri, L Muccioli, F Bisulli
    Journal of Clinical Medicine 15 (5), 1847 , 2026
    2026
  • Integration of intraoperative ultrasound and depth-electrode electrocorticography for resection guidance in epilepsy surgery: technical workflow and feasibility
    L Zanuttini, E Pasini, L Ferri, L Di Vito, A Scarabello, F Bisulli, M Martinoni
    Acta Neurochirurgica , 2026
    2026
  • CSF1R mutations in an Italian population of early-onset dementia: a case series
    B Pancaldi, A Mastrangelo, A Zilioli, E Ruggeri, V Vacchiano, E Pasini, ...
    Journal of Neurology 273 (2), 115 , 2026
    2026
  • Anti‐seizure prophylaxis in brain tumors: An Italian survey among epileptologists
    E Pasini, G Pauletto, M Maschio, R Michelucci, TSG of the Italian
    Epilepsia Open 11 (1), 376 , 2025
    2025
  • cfDNA-based liquid biopsy in the cerebrospinal fluid of Focal Drug-resistant Epilepsies caused by low-level mosaic, brain-only somatic mutations
    A Perciavalle, T Maloberti, L Ferri, E Cifaldi, R Minardi, L Licchetta, ...
    EPILEPSIA 66, S544-S545 , 2025
    2025
  • The challenge of ultra‐rarity: Dual diagnosis of Lafora disease and developmental encephalopathies linked to TRIO and SHANK3 pathogenic variants
    L Muccioli, F Bisulli, R Minardi, ML Valentino, M De Simone, RA Paroni, ...
    Epilepsia Open 10 (6), 1990-1996 , 2025
    2025
  • Standard complete blood count to predict long‐term outcomes in febrile infection–related epilepsy syndrome (FIRES): A multicenter study
    M Guillemaud, A Hanin, JJ Riviello, M Chavez, A Batra, M Berry, F Bisulli, ...
    Epilepsia 66 (12), 4780-4794 , 2025
    2025
    Citations: 4
  • New therapeutic strategies for Lafora disease: Evaluation of the safety, efficacy, pharmacokinetics and metabolomic profile of intravenous VAL-1221 treatment
    L Muccioli, M Tappatà, A Farolfi, PK Singh, E Pasini, S Mazzone, ...
    Neurotherapeutics, e00808 , 2025
    2025
    Citations: 1
  • Trends in epilepsy surgery in Italy before and after the COVID‐19 pandemic: A nationwide study
    G Didato, F Vigevano, L Tassi, R Guerrini, M De Curtis, L De Palma, ...
    Epilepsia 66 (11), 4183-4197 , 2025
    2025
  • Doping of a Borexino-like Liquid Scintillator with Tellurium-Diols
    HTJ Steiger, M Beretta, M Böhles, A Garfagnini, A Gavrikov, P Lombardi, ...
    arXiv preprint arXiv:2510.06665 , 2025
    2025
  • Sleep and Awake EEG Findings in a Patient With Lafora Disease: From Presymptomatic to Overt Disease Stage
    E Pasini, G Mainieri, I Minardi, S Mazzone, M Tappatà, L Muccioli, ...
    Neurology: Clinical Practice 15 (5), e200521 , 2025
    2025
  • Tumor‐related epilepsy in glioma: A multidisciplinary overview
    R Michelucci, G Pauletto, A Silvani, E Pasini, T Ius, M Martinoni, ...
    Epilepsia 66 (10), 3621-3641 , 2025
    2025
    Citations: 2
  • Generation of a human induced pluripotent stem cell line (CIBIOi007-A) from a Lafora disease patient
    G Trentini, G Cazzanelli, M Cardano, O Palumbo, M Benvenuto, ...
    Stem Cell Research 87, 103792 , 2025
    2025
  • Safety, efficacy and pharmacokinetic analysis of intravenous VAL-1221 treatment in Lafora disease
    L Muccioli, M Tappata, E Esposito, A Caravelli, C Cancellerini, E Pasini, ...
    EUROPEAN JOURNAL OF NEUROLOGY 32 , 2025
    2025
  • Secondary sclerosing cholangitis in critically ill patients with febrile infection-related epilepsy syndrome (FIRES): a case series
    L Muccioli, L Di Vito, E Pasini, L Ferri, G Vitale, A Granito, B Mostacci, ...
    Frontiers in neurology 16, 1557377 , 2025
    2025
    Citations: 2
  • New onset refractory status epilepticus: Long‐term outcomes beyond seizures
    PH Espino, K Eschbach, LJ Blank, MC Cervenka, E Muscal, ...
    Epilepsia 66 (4), 988-1005 , 2025
    2025
    Citations: 10

MOST CITED SCHOLAR PUBLICATIONS

  • LGI1 mutations in autosomal dominant and sporadic lateral temporal epilepsy
    C Nobile, R Michelucci, S Andreazza, E Pasini, SCE Tosatto, P Striano
    Human mutation 30 (4), 530-536 , 2009
    2009
    Citations: 173
  • Heterozygous reelin mutations cause autosomal-dominant lateral temporal epilepsy
    E Dazzo, M Fanciulli, E Serioli, G Minervini, P Pulitano, S Binelli, ...
    The American Journal of Human Genetics 96 (6), 992-1000 , 2015
    2015
    Citations: 159
  • Expression of 19 microRNAs in glioblastoma and comparison with other brain neoplasia of grades I–III
    M Visani, D De Biase, G Marucci, S Cerasoli, E Nigrisoli, MLB Reggiani, ...
    Molecular oncology 8 (2), 417-430 , 2014
    2014
    Citations: 119
  • Lateral temporal lobe epilepsies: clinical and genetic features
    R Michelucci, E Pasini, C Nobile
    Epilepsia 50, 52-54 , 2009
    2009
    Citations: 95
  • Myoclonus epilepsy and ataxia due to KCNC 1 mutation: Analysis of 20 cases and K + channel properties
    KL Oliver, S Franceschetti, CJ Milligan, M Muona, SA Mandelstam, ...
    Annals of neurology 81 (5), 677-689 , 2017
    2017
    Citations: 90
  • Aerosol drug delivery to spontaneously-breathing preterm neonates: lessons learned
    F Bianco, F Salomone, I Milesi, X Murgia, S Bonelli, E Pasini, R Dellacà, ...
    Respiratory Research 22 (1), 71 , 2021
    2021
    Citations: 69
  • The prognostic roles of gender and O6-methylguanine-DNA methyltransferase methylation status in glioblastoma patients: the female power
    E Franceschi, A Tosoni, S Minichillo, R Depenni, A Paccapelo, S Bartolini, ...
    World neurosurgery 112, e342-e347 , 2018
    2018
    Citations: 63
  • Myoclonus and seizures in progressive myoclonus epilepsies: pharmacology and therapeutic trials
    R Michelucci, E Pasini, P Riguzzi, E Andermann, R Kälviäinen, P Genton
    Epileptic Disorders 18 (s2), S145-S153 , 2016
    2016
    Citations: 63
  • Mild L afora disease: clinical, neurophysiologic, and genetic findings
    E Ferlazzo, L Canafoglia, R Michelucci, A Gambardella, E Gennaro, ...
    Epilepsia 55 (12), e129-e133 , 2014
    2014
    Citations: 62
  • Epilepsy in primary cerebral tumors: The characteristics of epilepsy at the onset (results from the PERNO study–P roject of E milia R omagna R egion on N euro‐O ncology)
    R Michelucci, E Pasini, S Meletti, E Fallica, R Rizzi, I Florindo, A Chiari, ...
    Epilepsia 54, 86-91 , 2013
    2013
    Citations: 59
  • From bench to bedside: in vitro and in vivo evaluation of a neonate-focused nebulized surfactant delivery strategy
    F Bianco, F Ricci, C Catozzi, X Murgia, M Schlun, A Bucholski, U Hetzer, ...
    Respiratory research 20 (1), 134 , 2019
    2019
    Citations: 58
  • EEG findings in COVID-19 related encephalopathy
    E Pasini, F Bisulli, L Volpi, I Minardi, M Tappatà, L Muccioli, U Pensato, ...
    Clinical Neurophysiology 131 (9), 2265 , 2020
    2020
    Citations: 54
  • The clinical phenotype of autosomal dominant lateral temporal lobe epilepsy related to reelin mutations
    R Michelucci, P Pulitano, C Di Bonaventura, S Binelli, C Luisi, E Pasini, ...
    Epilepsy & Behavior 68, 103-107 , 2017
    2017
    Citations: 54
  • DEPDC5 mutations are not a frequent cause of familial temporal lobe epilepsy
    P Striano, E Serioli, L Santulli, I Manna, A Labate, E Dazzo, E Pasini, ...
    Epilepsia 56 (10), e168-e171 , 2015
    2015
    Citations: 54
  • Spinal muscular atrophy associated with progressive myoclonic epilepsy: A rare condition caused by mutations in ASAH1
    G Rubboli, P Veggiotti, A Pini, A Berardinelli, G Cantalupo, E Bertini, ...
    Epilepsia 56 (5), 692-698 , 2015
    2015
    Citations: 54
  • Intravenous immunoglobulin therapy in COVID-19-related encephalopathy
    L Muccioli, U Pensato, G Bernabè, L Ferri, M Tappatà, L Volpi, I Cani, ...
    Journal of neurology 268 (8), 2671-2675 , 2021
    2021
    Citations: 52
  • Multiple variants in families with amyotrophic lateral sclerosis and frontotemporal dementia related to C9orf72 repeat expansion: further observations on their …
    MP Giannoccaro, A Bartoletti-Stella, S Piras, A Pession, P De Massis, ...
    Journal of neurology 264 (7), 1426-1433 , 2017
    2017
    Citations: 47
  • Low penetrance of autosomal dominant lateral temporal epilepsy in Italian families without LGI1 mutations
    R Michelucci, E Pasini, S Malacrida, P Striano, CD Bonaventura, ...
    Epilepsia 54 (7), 1288-1297 , 2013
    2013
    Citations: 47
  • Myoclonus: differential diagnosis and current management
    A Riva, G D'Onofrio, E Ferlazzo, A Pascarella, E Pasini, S Franceschetti, ...
    Epilepsia Open 9 (2), 486-500 , 2024
    2024
    Citations: 46
  • Pattern of care and effectiveness of treatment for glioblastoma patients in the real world: Results from a prospective population-based registry. Could survival differ in a …
    AA Brandes, E Franceschi, M Ermani, A Tosoni, F Albani, R Depenni, ...
    Neuro-oncology practice 1 (4), 166-171 , 2014
    2014
    Citations: 45